Top

Published in:

01-06-2009 | Review

Bone turnover markers: understanding their value in clinical trials and clinical practice

Authors: R. Civitelli, R. Armamento-Villareal, N. Napoli

Published in: Osteoporosis International | Issue 6/2009

Abstract

While bone mineral density (BMD) by dual-energy X-ray absorptiometry is the primary method of determining fracture risk, assessing bone turnover may add valuable information for the management of patients with low bone mass. Bone turnover markers (BTMs) are used in clinical trials where they can provide essential information on the biological efficacy of osteoporosis treatments. In such population-based studies, BTMs can predict fracture risk independent of BMD. When combined with BMD, they improve the fracture risk estimate above and beyond BMD alone in postmenopausal osteoporotic women. Since changes in bone turnover after the initiation of therapy with bone resorption inhibitors occur much more rapidly than changes in BMD, treatment efficacy could, in theory, be determined within weeks of using BTMs. However, such predictive value is limited by the large biological variability of these biochemical markers, even though newer automated methods have reduced their analytical variability. Consequently, widespread adoption as a means of predicting treatment efficacy in fracture prevention for individual patients cannot yet be recommended. BTMs may be useful for monitoring adherence to antiresorptive therapy and may aid in identifying patients for whom antiresorptive therapy is most appropriate. Thus, although BTMs are currently confined to clinical research applications, further improvement in assay precision may extend their diagnostic value in clinical settings.

World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.. World Health Organ Tech Rep Ser 843:1–129

ACOG practice bulletin (2004) Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 103:203–216 (Number 50, January 2003)

Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929–1936PubMedCrossRef

Burr DB (2003) Introduction—bone turnover and fracture risk. J Musculoskelet Neuronal Interact 3:408–409PubMed

Siris ES, Chen YT, Abbott TA et al (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108–1112PubMedCrossRef

Kanis JA, Johnell O, Oden A et al (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385–397PubMedCrossRef

Garnero P, Sornay-Rendu E, Chapuy MC et al (1996) Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349PubMed

Riggs BL, Melton LJ 3rd (2002) Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17:11–14PubMedCrossRef

Heaney RP (2003) Remodeling and skeletal fragility. Osteoporos Int 14(suppl 5):S12–S15

10.

Cummings SR, Karpf DB, Harris F et al (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRef

11.

Claudon A, Vergnaud P, Valverde C et al (2008) New automated multiplex assay for bone turnover markers in osteoporosis. Clin Chem 54:1554–1563PubMedCrossRef

12.

Garnero P, Vergnaud P, Hoyle N (2008) Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188–196PubMedCrossRef

13.

Schmidt-Gayk H, Spanuth E, Kötting J et al (2004) Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 42:90–95PubMedCrossRef

14.

Cremers S, Garnero P (2006) Biochemical markers of bone turnover in the clinical development of drugs for osteoporosis and metastatic bone disease: potential uses and pitfalls. Drugs 66:2031–2058PubMedCrossRef

15.

Abe Y, Ishikawa H, Fukao A (2008) Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women. Tohoku J Exp Med 214:51–59PubMedCrossRef

16.

Clemens JD, Herrick MV, Singer FR et al (1997) Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption. Clin Chem 43:2058–2063PubMed

17.

Hanson DA, Weis MA, Bollen AM et al (1992) A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251–1258PubMed

18.

Risteli J, Risteli L (1999) Products of bone collagen metabolism. In: Seibel M, Robins S, Bilezikian J (eds) Dynamics of bone and cartilage metabolism. Academic, San Diego, California, pp 275–288

19.

Risteli J, Elomaa I, Niemi S et al (1993) Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635–640PubMed

20.

Garnero P, Borel O, Delmas PD (2001) Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47:694–702PubMed

21.

Fledelius C, Johnsen AH, Cloos PA et al (1997) Characterization of urinary degradation products derived from type I collagen. Identification of a beta-isomerized Asp-Gly sequence within the C-terminal telopeptide (alpha1) region. J Biol Chem 272:9755–9763PubMedCrossRef

22.

Garnero P, Gineyts E, Schaffer AV et al (1998) Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum 41:354–360PubMedCrossRef

23.

Garnero P, Cloos P, Sornay-Rendu E et al (2002) Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study. J Bone Miner Res 17:826–833PubMedCrossRef

24.

Srivastava AK, Vliet EL, Lewiecki EM et al (2005) Clinical use of serum and urine bone markers in the management of osteoporosis. Curr Med Res Opin 21:1015–1026PubMedCrossRef

25.

Gunja-Smith Z, Boucek RJ (1981) Collagen cross-linking compounds in human urine. Biochem J 197:759–762PubMed

26.

Seibel MJ (2005) Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 26:97–122PubMed

27.

Kraenzlin ME, Kraenzlin CA, Meier C et al (2008) Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases. Clin Chem 54:1546–1553PubMedCrossRef

28.

Halleen JM, Alatalo SL, Janckila AJ et al (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47:597–600PubMed

29.

Hannon R, Blumsohn A, Naylor K et al (1998) Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 13:1124–1133PubMedCrossRef

30.

Prestwood KM, Pilbeam CC, Burleson JA et al (1994) The short-term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366–371PubMedCrossRef

31.

Eyre D (1992) New biomarkers of bone resorption. J Clin Endocrinol Metab 74:470A–470CPubMedCrossRef

32.

Delmas PD (1990) Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am 19:1–18PubMed

33.

Moro L, Pozzi Mucelli RS et al (1988) Urinary beta-1-galactosyl-0-hydroxylysine (GH) as a marker of collagen turnover of bone. Calcif Tissue Int 42:87–90PubMedCrossRef

34.

Price PA (1987) Vitamin K-dependent proteins. In: Cohn DV (ed) Calcium regulation and bone metabolism basic and clinical aspects. Amsterdam, Elsevier Science, The Netherlands, pp 419–425

35.

Dickson IR (1993) Bone. In: Royce PM, Steinmann B (eds) Connective tissue and its heritable disorders. Wiley-Liss, New York, pp 249–285

36.

Price PA (1985) Vitamin K-dependent formation of bone Gla protein (osteocalcin) and its function. Vitam Horm 42:65–108PubMedCrossRef

37.

Riggs BL, Tsai KS, Mann KG (1986) Effect of acute increases in bone matrix degradation on circulating levels of bone-Gla protein. J Bone Miner Res 1:539–542PubMed

38.

Garnero P, Grimaux M, Seguin P et al (1994) Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res 9:255–264PubMed

39.

Taylor AK, Linkhart S, Mohan S et al (1990) Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J Clin Endocrinol Metab 7:467–472CrossRef

40.

Low MG (1987) Biochemistry of the glycosyl–phosphatidylinositol membrane protein anchors. Biochem J 244:1–13PubMed

41.

Harris H (1990) The human alkaline phosphatases: what we know and what we don’t know. Clin Chim Acta 186:133–150PubMedCrossRef

42.

Green S, Anstiss CL, Fishman WH (1971) Automated differential isoenzyme analysis. II. The fractionation of serum alkaline phosphatases into “liver”, “intestinal” and “other” components. Enzymologia 41:9–26PubMed

43.

Farley JR, Chesnut CH 3rd, Baylink DJ (1981) Improved method for quantitative determination in serum of alkaline phosphatase of skeletal origin. Clin Chem 27:2002–2007PubMed

44.

Liu SH, Yang RS, al-Shaikh R et al (1995) Collagen in tendon, ligament, and bone healing. A current review. Clin Orthop Relat Res 318:265–278PubMed

45.

Woo SLY, An KN, Arnoczky SP et al (1994) Anatomy, biology and biomechanics of tendon, ligament and meniscus. In: Simon SR (ed) Orthopaedic basic science. American Academy of Orthopaedic Surgeons, Chicago, pp 45–88

46.

Smedsrod B, Melkko J, Risteli L et al (1990) Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem J 271:345–350PubMed

47.

Lüftner D, Jozereau D, Schildhauer S et al (2005) PINP as serum marker of metastatic spread to the bone in breast cancer patients. Anticancer Res 25:1491–1499PubMed

48.

Toivonen J, Tähtelä R, Laitinen K et al (1998) Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138:667–673PubMedCrossRef

49.

Crofton PM, Wade JC, Taylor MR et al (1997) Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 43:1577–1581PubMed

50.

Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study. J Bone Miner Res 15:1526–1536PubMedCrossRef

51.

Garnero P, Hausherr E, Chapuy MC et al (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 11:1531–1538PubMedCrossRef

52.

van Daele PL, Seibel MJ, Burger H et al (1996) Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam Study. BMJ 312:482–483PubMed

53.

Ross PD, Kress BC, Parson RE et al (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11:76–82PubMedCrossRef

54.

Bauer DC, Sklarin PM, Stone KL et al (1999) Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res 14:1404–1410PubMedCrossRef

55.

Eastell R, Barton I, Hannon RA et al (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051–1056PubMedCrossRef

56.

Eastell R, Hannon RA, Garnero P et al (2007) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res 22:1656–1660PubMedCrossRef

57.

Reginster JY, Adami S, Lakatos P et al (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE Study. Ann Rheum Dis 65:654–661PubMedCrossRef

58.

Recker R, Stakkestad JA, Chesnut CH 3rd et al (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899PubMedCrossRef

59.

Bauer DC, Garnero P, Hochberg MC, for the Fracture Intervention Research Group et al (2006) Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21:292–299PubMedCrossRef

60.

Black DM, Delmas PD, Eastell R et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822PubMedCrossRef

61.

Weinstein RS, Parfitt AM, Marcus R et al (2003) Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 14:814–822PubMedCrossRef

62.

Bone HG, Bolognese MA, Yuen CK et al (2008) Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 93:2149–2157PubMedCrossRef

63.

Anastasilakis AD, Goulis DG, Polyzos SA, et al (2009) No difference between strontium ranelate and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial. Clin Endocrinol (Oxf). doi:10.1111/j.1365-2265.2008.03342.x

64.

Hochberg MC, Greenspan S, Wasnich RD et al (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586–1592PubMedCrossRef

65.

Raisz L, Smith JA, Trahiotis M et al (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615–620PubMedCrossRef

66.

Braga de Castro Machado A, Hannon R, Eastell R (1999) Monitoring alendronate therapy for osteoporosis. J Bone Miner Res 14:602–608PubMedCrossRef

67.

Aoshima H, Kushida K, Takahashi M et al (1998) Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22:73–78PubMedCrossRef

68.

Borderie D, Roux C, Toussaint B et al (2001) Variability in urinary excretion of bone resorption markers: limitations of a single determination in clinical practice. Clin Biochem 34:571–577PubMedCrossRef

69.

Ju HS, Leung S, Brown B et al (1997) Comparison of analytical performance and biological variability of three bone resorption assays. Clin Chem 43:1570–1576PubMed

70.

Gluer C (1999) Monitoring skeletal changes by radiologic techniques. J Bone Miner Res 14:1952–1962PubMedCrossRef

71.

Shepherd JA, Morgan SL, Lu Y (2008) Comparing BMD results between two similar DXA systems using the generalized least significant changes. J Clin Densitom 11:237–242PubMedCrossRef

72.

Bauer DC, Garnero P, Bilezikian JP et al (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370–1375PubMedCrossRef

73.

Raehl CL, Bond CA, Woods TJ et al (2006) Screening tests for intended medication adherence among the elderly. Ann Pharmacother 40:888–893PubMedCrossRef

74.

McHorney CA, Schousboe JT, Cline RR et al (2007) The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.. Curr Med Res Opin 23:3137–3152 (Erratum in: Curr Med Res Opin. 2008;24:707)PubMedCrossRef

75.

Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef

76.

Cramer JA, Amonkar MM, Hebborn A et al (2005) Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 21:1453–1460PubMedCrossRef

77.

Solomon DH, Avorn J, Katz JN et al (2005) Compliance with osteoporosis medications. Arch Intern Med 165:2414–2419PubMedCrossRef

78.

Cooper A, Drake J, Brankin E (2006) Treatment persistence with once monthly ibandronate and patient support vs once-weekly alendronate: results from the PERSIST Study. Int J Clin Pract 60:896–905PubMedCrossRef

79.

Seibel MJ (2006) Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27:123–138PubMed

80.

Russell RG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone 25:97–106PubMedCrossRef

81.

Clowes JA, Peel NF, Eastell R (2004) The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab 89:1117–1123PubMedCrossRef

82.

Delmas PD, Vrijens B, Roux C et al (2003) A reinforcement message based on bone turnover markers response influences long-term persistence with risedronate in osteoporosis: the IMPACT Study. J Bone Miner Res 18(suppl 2):S374

83.

Civitelli R, Gonnelli S, Zacchei F et al (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268–1274PubMedCrossRef

84.

Chesnut CH III, Bell NH, Clark GS et al (1997) Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 102:29–37PubMedCrossRef

85.

Uebelhart D, Schlemmer A, Johansen JS et al (1991) Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab 72:367–373PubMedCrossRef

86.

Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637–645PubMedCrossRef

87.

Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRef

88.

Schaffler MB, Choi K, Milgrom C (1995) Aging and matrix microdamage accumulation in human compact bone. Bone 17:521–525PubMedCrossRef

89.

Mashiba T, Hirano T, Turner CH et al (2000) Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613–620PubMedCrossRef

90.

Bouxsein ML (2003) Bone quality: where do we go from here? Osteoporos Int 14(suppl 5):118–127CrossRef

91.

Visekruna M, Wilson D, McKiernan FE (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952PubMedCrossRef

92.

Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350PubMedCrossRef

Title: Bone turnover markers: understanding their value in clinical trials and clinical practice
Authors: R. Civitelli
R. Armamento-Villareal
N. Napoli
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 6/2009
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-009-0838-9

At a glance: The STEP trials

Springer Medicine

Bone turnover markers: understanding their value in clinical trials and clinical practice

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2009

The Third Meeting on Bone Quality, June 2008

Investigation of bone with synchrotron radiation imaging: from micro to nano

RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction

Fourier transform infrared analysis and bone

The role of osteocytes in bone mechanotransduction

Epidemiology of lumbar osteoporosis and osteoarthritis and their causal relationship—is osteoarthritis a predictor for osteoporosis or vice versa?: The Miyama study